ME Therapeutics Holdings (CNSX:METX) - Stock Price, News & Analysis

METX Stock Overview

A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details

METX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the Canadian market

Does not have a meaningful market cap (CA$90M)

ME Therapeutics Holdings Inc. Competitors

Satellos Bioscience

TSX:MSCL

CA$79.5m

Covalon Technologies

TSXV:COV

CA$100.0m

Oncolytics Biotech

TSX:ONC

CA$101.7m

Medicenna Therapeutics

TSX:MDNA

CA$134.4m

Price History & Performance

Summary of all time highs, changes and price drops for ME Therapeutics Holdings
Historical stock prices
Current Share Price	CA$3.80
52 Week High	CA$7.50
52 Week Low	CA$0.26
Beta	0
11 Month Change	-30.91%
3 Month Change	153.33%
1 Year Change	3,700.00%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	520.41%

Recent updates

Shareholder Returns

	METX	CA Biotechs	CA Market
7D	8.6%	8.5%	0.5%
1Y	3,700.0%	13.2%	22.2%

Return vs Industry: METX exceeded the Canadian Biotechs industry which returned 13.2% over the past year.

Return vs Market: METX exceeded the Canadian Market which returned 22.2% over the past year.

Price Volatility

Is METX's price volatile compared to industry and market?
METX volatility
METX Average Weekly Movement	75.2%
Biotechs Industry Average Movement	11.5%
Market Average Movement	8.4%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	3.0%

Stable Share Price: METX's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: METX's weekly volatility has increased from 49% to 75% over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Salim Dhanji	www.metherapeutics.com

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.

ME Therapeutics Holdings Inc. Fundamentals Summary

How do ME Therapeutics Holdings's earnings and revenue compare to its market cap?
METX fundamental statistics
Market cap	CA$89.81m
Earnings (TTM)	CA$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is METX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
METX income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$0
Earnings	CA$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did METX perform over the long term?

See historical performance and comparison

ME Therapeutics Holdings CNSX:METX Stock Report